Category - Developments

Developments

Emergent donates 50,000 smallpox vaccine doses in response to WHO’s mpox declaration

Emergent BioSolutions (NYSE:EBS) announced its pledge to donate 50,000 doses of its ACAM2000 smallpox vaccine through Direct Relief in response to WHO’s declaration that the upsurge of mpox in the Democratic Republic of...

August 20, 2024

Developments

Tonix enrolls first patient in Phase 2 study of TX1300 for acute cocaine intoxication

Tonix Pharmaceuticals (NASDAQ:TNXP) announced the first patient dosing in its Phase 2 trial of the recombinant enzyme TNX-1300 for treating life-threatening cocaine intoxication in patients presenting to the emergency...

August 20, 2024

Developments

First participant dosed in Monte Rosa’s Phase 1 study of MRT-6160 for autoimmune disease

Monte Rosa Therapeutics (NASDAQ:GLUE) announced that the first participant has been dosed in its Phase 1 healthy volunteer study evaluating MRT-6160, a VAV1-directed MGB being developed for systemic and neurological...

August 19, 2024

Developments

Optimi Health announces export of first MDMA capsules for PTSD to Australia

Optimi Health (CSE:OPTI; OTCQX:OPTHF; FSE:8BN) reports completion of its inaugural export of GMP-validated, 3,4-methylenedioxymethamphetamine (MDMA) capsules to Australia for the treatment of patients with post...

August 16, 2024

Developments

Perimeter reports progress on several fronts

Perimeter Medical Imaging AI (TSX:PINK; OTC:PYNKF; FSE:4PC) highlighted several positive developments and achievements in its Q2 report and conference call yesterday. Perimeter is a medical technology company working to...

August 15, 2024

Developments

Zomedica partners with SIRE to expand sales into Central America

Zomedica (NYSEA:ZOM) announced the expansion of its sales reach into Costa Rica through a partnership with SIRE Veterinario, which will be the exclusive distributor of Zomedica products in that country. “Our...

August 14, 2024

Developments

FDA accepts scPharmaceuticals sNDA to expand heart failure drug indication

scPharmaceuticals (NASDAQ:SCPH) has announced FDA approval of its supplemental NDA (sNDA) for FUROSCIX, expanding its indication to New York Heart Association (NYHA) Class IV chronic heart failure patients. Previously...

August 12, 2024

Developments

NIH awards grant to Marker Therapeutics through SBIR program

Marker Therapeutics (NASDAQ:MRKR) has announced that it has been awarded a $2 million grant from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program to support the clinical...

August 12, 2024

Developments

OneMedNet successfully integrates its proprietary AI technology into its data curation process, boosting efficiency up to 5X

OneMedNet (NASDAQ:ONMD) reported today that it has successfully integrated its proprietary AI technology into its data curation process, ensuring rapid and precise de-identification of patient data. This innovation...

August 9, 2024

Developments

Awakn screens first patient in Phase 3 trial of treatment for AUD

Awakn Life Sciences (CSE:AWKN; OTCQB:AWKNF; FSE:954) has announced that the first patient has been screened in its landmark MORE-KARE Phase 3 trial of AWKN-001, an investigational, novel medication-assisted treatment...

August 9, 2024

Category - Developments

Emergent donates 50,000 smallpox vaccine doses in response to WHO’s mpox declaration

Tonix enrolls first patient in Phase 2 study of TX1300 for acute cocaine intoxication

First participant dosed in Monte Rosa’s Phase 1 study of MRT-6160 for autoimmune disease

Optimi Health announces export of first MDMA capsules for PTSD to Australia

Perimeter reports progress on several fronts

Zomedica partners with SIRE to expand sales into Central America

FDA accepts scPharmaceuticals sNDA to expand heart failure drug indication

NIH awards grant to Marker Therapeutics through SBIR program

OneMedNet successfully integrates its proprietary AI technology into its data curation process, boosting efficiency up to 5X

Awakn screens first patient in Phase 3 trial of treatment for AUD

General

More